The endothelin B receptor plays a crucial role in the adhesion of neutrophils to the endothelium in sickle cell disease

Haematologica

Volumn 102, Issue 7, 2017, Pages 1161-1172

  Koehl, Bérengère ^a,e   Nivoit, Pierre ^b   El Nemer, Wassim ^a   Lenoir, Olivia ^b,d   Hermand, Patricia ^a   Pereira, Catia ^a   Brousse, Valentine ^f   Guyonnet, L ^b,c   Ghinatti, Giulia ^b   Benkerrou, Malika ^e   Colin, Yves ^a   Le van Kim, Caroline ^a   Tharaux, Pierre Louis ^b  

^a Laboratoire d'Excellence GR Ex   (France)

^b PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^c LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e HÔPITAL ROBERT DEBRÉ   (France)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; ENDOTHELIN 1; ENDOTHELIN B RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; PADGEM PROTEIN; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; CALCIUM; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST;

ADHESION; ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM SIGNALING; CHILD; CONTROLLED STUDY; ENDOTHELIUM CELL; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; INTRAVITAL MICROSCOPY; MAJOR CLINICAL STUDY; MICROCIRCULATION; MICROFLUIDIC ANALYSIS; MOUSE; NEUTROPHIL ADHESION; NONHUMAN; PRESCHOOL CHILD; QUANTITATIVE MICROFLUIDIC FLUORESCENCE MICROSCOPY; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; SICKLE CELL ANEMIA; UPREGULATION; VASOCONSTRICTION; ANIMAL; BLOOD; CASE CONTROL STUDY; CELL ADHESION; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; GENETICS; HEMODYNAMICS; IMMUNOLOGY; LEUKOCYTE ACTIVATION; LEUKOCYTE COUNT; LEUKOCYTE ROLLING; METABOLISM; NEUTROPHIL; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; VASCULAR ENDOTHELIUM;

ADOLESCENT; ANEMIA, SICKLE CELL; ANIMALS; CALCIUM; CASE-CONTROL STUDIES; CD11B ANTIGEN; CELL ADHESION; CELL SURVIVAL; CHILD; CHILD, PRESCHOOL; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ENDOTHELIN A RECEPTOR ANTAGONISTS; ENDOTHELIN B RECEPTOR ANTAGONISTS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HEMODYNAMICS; HUMANS; LEUKOCYTE COUNT; LEUKOCYTE ROLLING; MACROPHAGE-1 ANTIGEN; MICE; NEUTROPHIL ACTIVATION; NEUTROPHILS; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85021410858     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2016.156869     Document Type: Article

References (60)

1. Kaul DK, Finnegan E, Barabino GA. Sickle red cell-endothelium interactions. Microcirculation. 2009;16(1):97-111.
2. Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci USA. 2002;99(5):3047-3051.
3. Manwani D, Frenette PS. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood. 2013;122(24):3892-3898.
4. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639-1644.
5. Anyaegbu CC, Okpala IE, Akren'Ova YA, Salimonu LS. Peripheral blood neutrophil count and candidacidal activity correlate with the clinical severity of sickle cell anaemia (SCA). Eur J Haematol. 1998;60(4):267-268.
6. Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood. 1994;84(2):643-649.
7. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1):288-294.
8. Wigfall DR, Ware RE, Burchinal MR, Kinney TR, Foreman JW. Prevalence and clinical correlates of glomerulopathy in children with sickle cell disease. J Pediatr. 2000;136(6):749-753.
9. Zhang D, Xu C, Manwani D, Frenette PS. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood. 2016;127(7):801-809.
10. Okpala I, Daniel Y, Haynes R, Odoemene D, Goldman J. Relationship between the clinical manifestations of sickle cell disease and the expression of adhesion molecules on white blood cells. Eur J Haematol. 2002;69(3):135-144.
11. Lard LR, Mul FP, de Haas M, Roos D, Duits AJ. Neutrophil activation in sickle cell disease. J Leukoc Biol. 1999;66(3):411-415.
12. Fadlon E, Vordermeier S, Pearson TC, et al. Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. Blood. 1998;91(1):266-274.
13. Lum AF, Wun T, Staunton D, Simon SI. Inflammatory potential of neutrophils detected in sickle cell disease. Am J Hematol. 2004;76(2):126-133.
14. Benkerrou M, Delarche C, Brahimi L, et al. Hydroxyurea corrects the dysregulated Lselectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia. Blood. 2002;99(7):2297-2303.
15. Davenport AP, Hyndman KA, Dhaun N, et al. Endothelin. Pharmacol Rev. 2016;68(2):357-418.
16. Phelan M, Perrine SP, Brauer M, Faller DV. Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture. J Clin Invest. 1995;96(2):1145-1151.
17. Firth J, Ratcliffe J. Organ distribution of the three rat endothelin messengers RNAs and the effects of ischemia on renal gene expression. J Clin Invest. 1992;90(3):1023-1031.
18. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol. 2001;41:851-876.
19. Sabaa N, de Franceschi L, Bonnin P, et al. Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest. 2008;118(5):1924-1933.
20. Trudel M, Saadane N, Garel MC, et al. Towards a transgenic mouse model of sickle cell disease: hemoglobin SAD. EMBO J. 1991;10(11):3157-3165.
21. Brun M, Bourdoulous S, Couraud PO, Elion J, Krishnamoorthy R, Lapoumeroulie C. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. Pharmacogenomics J. 2003;3(4):215-226.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402-408.
23. Hidalgo A, Chang J, Jang JE, Peired AJ, Chiang EY, Frenette PS. Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury. Nat Med. 2009;15(4):384-391.
24. Elferink JG, de Koster BM. Stimulation and inhibition of neutrophil chemotaxis by endothelin-3. J Cardiovasc Pharmacol. 1995;26 (Suppl 3):S142-144.
25. Elferink JG, de Koster BM. The effect of endothelin-2 (ET-2) on migration and changes in cytosolic free calcium of neutrophils. Naunyn Schmiedebergs Arch Pharmacol. 1996;353(2):130-135.
26. Elferink JG, de Koster BM. Modulation of human neutrophil chemotaxis by the endothelin-B receptor agonist sarafotoxin S6c. Chem Biol Interact. 1996;101(3):165-174.
27. Graido-Gonzalez E, Doherty JC, Bergreen EW, Organ G, Telfer M, McMillen MA. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. Blood. 1998;92(7):2551-2555.
28. Werdehoff SG, Moore RB, Hoff CJ, Fillingim E, Hackman AM. Elevated plasma endothelin-1 levels in sickle cell anemia: relationships to oxygen saturation and left ventricular hypertrophy. Am J Hematol. 1998;58(3):195-199.
29. Rybicki AC, Benjamin LJ. Increased levels of endothelin-1 in plasma of sickle cell anemia patients. Blood. 1998;92(7):2594-2596.
30. Tharaux PL, Hagege I, Placier S, et al. Urinary endothelin-1 as a marker of renal damage in sickle cell disease. Nephrol Dial Transplant. 2005;20(11):2408-2413.
31. Chaar V, Tarer V, Etienne-Julan M, Diara JP, Elion J, Romana M. ET-1 and ecNOS gene polymorphisms and susceptibility to acute chest syndrome and painful vaso-occlusive crises in children with sickle cell anemia. Haematologica. 2006;91(9):1277-1278.
32. Lionnet F, Bachmeyer C, Stankovic K, Tharaux PL, Girot R, Aractingi S. Efficacy of the endothelin receptor blocker bosentan for refractory sickle cell leg ulcers. Br J Haematol. 2008;142(6):991-992.
33. Lopez Farre A, Riesco A, Moliz M, et al. Inhibition by L-arginine of the endothelinmediated increase in cytosolic calcium in human neutrophils. Biochem Biophys Res Commun. 1991;178(3):884-891.
34. Ishida K, Takeshige K, Minakami S. Endothelin-1 enhances superoxide generation of human neutrophils stimulated by the chemotactic peptide N-formyl-methionylleucyl-phenylalanine. Biochem Biophys Res Commun. 1990;173(2):496-500.
35. Gomez-Garre D, Guerra M, Gonzalez E, et al. Aggregation of human polymorphonuclear leukocytes by endothelin: role of platelet-activating factor. Eur J Pharmacol. 1992;224(2-3):167-172.
36. Camus SM, De Moraes JA, Bonnin P, et al. Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease. Blood. 2015;125(24):3805-3814.
37. Zhang D, Chen G, Manwani D, et al. Neutrophil ageing is regulated by the microbiome. Nature. 2015;525(7570):528-532.
38. Trudel M, De Paepe ME, Chretien N, et al. Sickle cell disease of transgenic SAD mice. Blood. 1994;84(9):3189-3197.
39. De Franceschi L, Brugnara C, Rouyer-Fessard P, Jouault H, Beuzard Y. Formation of dense erythrocytes in SAD mice exposed to chronic hypoxia: evaluation of different therapeutic regimens and of a combination of oral clotrimazole and magnesium therapies. Blood. 1999;94(12):4307-4313.
40. de Franceschi L, Baron A, Scarpa A, et al. Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation. Blood. 2003;102(3):1087-1096.
41. De Paepe ME, Trudel M. The transgenic SAD mouse: a model of human sickle cell glomerulopathy. Kidney Int. 1994;46(5): 1337-1345.
42. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun. 1994;199(3):1461-1465.
43. Ohuchi T, Kuwaki T, Ling GY, et al. Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice. Am J Physiol. 1999;276(4 Pt 2):R1071-1077.
44. Pollock JS, Pollock DM. Endothelin and NOS1/nitric oxide signaling and regulation of sodium homeostasis. Curr Opin Nephrol Hypertens. 2008;17(1):70-75.
45. Goddard J, Eckhart C, Johnston NR, Cumming AD, Rankin AJ, Webb DJ. Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptormediated and nitric oxide-dependent mechanism. J Am Soc Nephrol. 2004;15(10):2601-2610.
46. Goligorsky MS, Tsukahara H, Magazine H, Andersen TT, Malik AB, Bahou WF. Termination of endothelin signaling: role of nitric oxide. J Cell Physiol. 1994;158(3):485-494.
47. Wright CD, Cody WL, Dunbar JB Jr, Doherty AM, Hingorani GP, Rapundalo ST. Characterization of endothelins as chemoattractants for human neutrophils. Life Sci. 1994;55(21):1633-1641.
48. Helset E, Lindal S, Olsen R, Myklebust R, Jorgensen L. Endothelin-1 causes sequential trapping of platelets and neutrophils in pulmonary microcirculation in rats. Am J Physiol. 1996;271(4 Pt 1):L538-546.
49. Elferink JG, de Koster BM. Endothelininduced activation of neutrophil migration. Biochem Pharmacol. 1994;48(5):865-871.
50. Zarpelon AC, Pinto LG, Cunha TM, et al. Endothelin-1 induces neutrophil recruitment in adaptive inflammation via TNFalpha and CXCL1/CXCR2 in mice. Can J Physiol Pharmacol. 2012;90(2):187-199.
51. Sessa WC, Kaw S, Hecker M, Vane JR. The biosynthesis of endothelin-1 by human polymorphonuclear leukocytes. Biochem Biophys Res Commun. 1991;174(2):613-618.
52. Makis AC, Hatzimichael EC, Kolios G, Bourantas KL. Circulating endothelin-3 levels in patients with sickle cell disease during hydroxyurea treatment. Haematologica. 2004;89(3):360-361.
53. Espinosa G, Lopez Farre A, Cernadas MR, et al. Role of endothelin in the pathophysiology of renal ischemia-reperfusion in normal rabbits. Kidney Int. 1996;50(3):776-782.
54. Farmer DG, Kaldas F, Anselmo D, et al. Tezosentan, a novel endothelin receptor antagonist, markedly reduces rat hepatic ischemia and reperfusion injury in three different models. Liver Transplant. 2008;14(12): 1737-1744.
55. Khimenko PL, Moore TM, Taylor AE. Blocked ETA receptors prevent ischemia and reperfusion injury in rat lungs. J Appl Physiol. 1996;80(1):203-207.
56. Ghandour S, Cetinel S, Kurtel H. Endothelin-3 induced mesenteric vasoconstriction and PMN infiltration in the rat small intestine: role of endothelin receptors. Regul Pept. 2004;119(1-2):125-131.
57. Lopez-Farre A, Caramelo C, Esteban A, et al. Effects of aspirin on platelet-neutrophil interactions. Role of nitric oxide and endothelin-1. Circulation. 1995;91(7):2080-2088.
58. Zouki C, Baron C, Fournier A, Filep JG. Endothelin-1 enhances neutrophil adhesion to human coronary artery endothelial cells: role of ET(A) receptors and platelet-activating factor. Br J Pharmacol. 1999;127(4):969-979.
59. Fernandez-Patron C, Zouki C, Whittal R, Chan JS, Davidge ST, Filep JG. Matrix metalloproteinases regulate neutrophil-endothelial cell adhesion through generation of endothelin-1[1-32]. FASEB J. 2001;15(12): 2230-2240.
60. Kim M, Carman CV, Springer TA. Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science. 2003;301(5640):1720-1725.